Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month.

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Percheron Therapeutics has reported a significant change in its substantial shareholding, as Platinum Investment ...

Percheron Capital is a private equity firm focused on partnering with exceptional teams to build market-leading essential services businesses. The firm’s purpose is to support high-quality ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Percheron Therapeutics Limited announced the cessation of certain securities as of December 20, 2024 ...

Percheron Therapeutics (AU:PER) has released an update. Percheron Therapeutics is on the brink of a significant milestone as it prepares to unveil initial results from its phase IIb trial of ...

Percheron Therapeutics (AU:PER) has released an update. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with ...

Percheron Therapeutics Limited has announced that Powerhouse Ventures Limited has become a substantial holder in the company, acquiring a 5.058% voting power through the purchase of 55,000,000 ...